Richardson PG et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): Results from the expansion cohorts of a Phase 1 dose-escalation study. Proc ASH 2011;Abstract 301.

Kumar S et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: Results from a phase 1 dose-escalation study. Proc ASH 2011;Abstract 816.

Berdeja JG et al. Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Proc ASH 2011;Abstract 479.

Dr Lonial is Vice Chair of Clinical Affairs and Director of Translational Research at the Emory University School of Medicine’s Winship Cancer Institute in Atlanta, Georgia.

Dr Richardson is Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute in Boston, Massachusetts.